Search clinical trials for: evolocumab

Total 139 results

Policlinico Casilino ASL RMB
IRCCS San Raffaele

Unknown

Evolocumab Plus Ezetimibe in Haemodialized Statin-intolerant Patients With Hypercholesterolemia

Hypercholesterolemia | CKD Stage 5 | Chronic Kidney Disease Requiring Chronic Dialysis

Italy
Amgen
Organization of Teratology Information Specialists (OTIS) Research Center...

Terminated

Evolocumab Pregnancy Exposure Registry

Hypercholesterolemia; ASCVD; Pregnancy
Hamid Al-Essa Organ Transplant Center

Completed

PCSK 9 Inhibition as Secondary Prevention in Renal Transplant Patients

Kideny Transplant Recipients With High Cardiovascular Risk Score

Kuwait
Beijing Anzhen Hospital

Unknown

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With High Risk Coronary Artery Disease (FORWARD) (FORWARD)

Dyslipidemia | High Risk Coronary Artery Disease

China
Amgen

Completed

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4 (GAUSS-4)

Hypercholesterolemia

Japan
University Medical Centre Ljubljana

Unknown

Markers of Cardiovascular Risk in Patients With Premature Coronary Artery Disease and Treatment (GEBI)

Inflammation | Acute Coronary Syndrome | Lipoproteinemia | Genetic Polymorphisms | Premature Coronary Heart Disease

Slovenia
Rigshospitalet, Denmark

Withdrawn

Vascular Inflammation and Cholesterol Lowering Therapy

Lipid Lowering, Vascular Inflammation

Denmark
Johns Hopkins University
American Heart Association

Completed

Effect of Evolocumab on Coronary Endothelial Function (EVOLVE)

Coronary Artery Disease | Human Immunodeficiency Virus

United States
Amgen

Completed

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2 (GAUSS-2)

Hyperlipidemia

United States, Denmark, Belgium, Germany, Hong Kong, Netherlands, France, Australia, Canada, South Africa, United Kingdom, Spain, Poland, Switzerland
Policlinico Casilino ASL RMB
IRCCS San Raffaele

Unknown

Evolocumab Plus Ezetimibe in High Risk Haemodialized Statin Intolerant Patients

Hypercholesterolemia | Chronic Kidney Disease Requiring Chronic Dialysis

Italy
Esperion Therapeutics, Inc.

Completed

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy

Hypercholesterolemia

United States
Leonardo Clavijo
Amgen

Unknown

Effect of Evolocumab in Patients With Critical Limb Ischemia (Evol-CLI) (Evol-CLI)

Critical Limb Ischemia

United States
Leonardo Clavijo
Amgen

Unknown

Effect of Evolocumab in Functional Status and LDL Oxidation of Patients With Peripheral Arterial Disease (Evol-PAD)

Peripheral Arterial Disease

United States
University of British Columbia

Unknown

Evolocumab for PCSK9 Lowering in Early Acute Sepsis (The PLEASe Study) (PLEASe)

Sepsis

Canada
ECRI bv
GE Healthcare; Amgen; HeartFlow, Inc.

Withdrawn

Multislice Computed Tomography Assessment of PCSK9 Inhibition on Coronary Perfusion (MARKOV)

Coronary Artery Disease
Affiliated Hospital to Academy of Military Medical...

Completed

Application of Simethicone in Esophagogastroscopy

Gastric Disease

China
University Hospital Inselspital, Berne
Amgen; University of Bern

Completed

EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS) (EVOPACS)

Acute Coronary Syndrome

Switzerland
Amgen

Completed

Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2 (RUTHERFORD-2)

Hyperlipidemia

Canada, France, Netherlands, United Kingdom, New Zealand, South Africa, Spain, United States, Australia, Germany, Sweden, Hong Kong, Switzerland, Norway
Amgen

Completed

Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia (OSLER-2)

Hyperlipidemia and Mixed Dyslipidemia

United States, Canada, Denmark, France, Italy, Belgium, Czechia, Taiwan, Japan, Switzerland, Germany, United Kingdom, Korea, Republic of, Hong Kong, Netherlands, New Zealand, South Africa, Australia, Spain, Austria, Hungary, Russian... and more
Amgen

Completed

Open-label Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab

Hypercholesterolemia

Canada, Netherlands, Spain, Belgium, United States, Russian Federation, Czechia, Mexico, Korea, Republic of, Australia, United Kingdom, Argentina, Israel, France, Hungary, Germany, Greece, Poland, Switzerland, Italy, Brazil, Sweden, Norwa... and more
Amgen

Completed

GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound (GLAGOV)

Hypercholesterolemia

United States, Canada, Denmark, Germany, Italy, Netherlands, Spain, Sweden, Belgium, Taiwan, Russian Federation, France, Czechia, Mexico, Korea, Republic of, Australia, United Kingdom, Argentina, Israel, Hungary, South Africa, Greece and more
UMC Utrecht
Erasmus Medical Center; Academisch Medisch Centrum - Universiteit van Amsterdam... and other collaborators

Unknown

Effects of Evolocumab Versus Placebo Added to Standard Lipid-lowering Therapy on Fasting and Post Fat Load Lipids in Patients With Familial Dysbetalipoproteinemia (EVOLVE-FD)

Hyperlipoproteinemia Type III | Familial Dysbetalipoproteinemia
Amgen

Completed

Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia (BERSON)

Diabetes, Hyperlipidemia, Mixed Dyslipidemia

United States, Canada, France, Korea, Republic of, China, Argentina, Russian Federation, Colombia, Turkey, Brazil
Amgen

Completed

Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities (TESLA)

Homozygous Familial Hypercholesterolemia

New Zealand, South Africa, France, United States, Spain, Belgium, Czechia, Italy, Netherlands, Hong Kong, Canada, Lebanon
Amgen

Completed

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3 (GAUSS-3)

Hyperlipidemia

Canada, Denmark, France, United States, Czechia, New Zealand, Australia, South Africa, Italy, United Kingdom, Netherlands, Germany, Norway
Amgen

Completed

Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen

Mixed Dyslipidemia | Primary Hypercholesterolemia

United States, Canada
Amgen

Completed

A Study to Evaluate Tolerability and Efficacy of Evolocumab (AMG 145) in Japanese Subjects (AMG145)

Hypercholesterolemia and High Risk for Cardiovascular Events

Japan
Amgen

Completed

Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Evolocumab (AMG 145) in Adults With Hyperlipidemia on Stable Doses of a Statin

Hyperlipidemia
Amgen

Completed

Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody (FLOREY)

Primary Hyperlipidemia and Mixed Dyslipidemia

Australia
Amgen

Completed

Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia (BANTING)

Type 2 Diabetes | Hypercholesterolemia | Mixed Dyslipidemia

United States, Italy, Belgium, Spain, Canada, Poland, Mexico
Pontificia Universidad Catolica de Chile

Completed

Premedication With Simethicone or Simethicone Plus N-acetylcysteine in Improving Visibility During Upper Endoscopy (PRUE)

Stomach Neoplasms

Chile
Hospital General Universitario Gregorio Marañon

Completed

Evolocumab Versus LDL Apheresis in Patients With Hypercholesterolemia

Hypercholesterolemia

Spain
Amgen

Completed

Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects (EBBINGHAUS)

Dyslipidemia

United States, Belgium, Denmark, Finland, France, Italy, Spain, Hungary, Poland, Germany, Czechia, Turkey, United Kingdom, Malaysia, Australia, Hong Kong, New Zealand, Canada, South Africa, Greece, Portugal, Netherlands, Russian Federation and more
Wolfson Medical Center

Unknown

The Effect of Voltaren-ophtha 0.1% Eye Drops on INR Levels (International Normalized Ratio) in Patients Taking Warfarin

Blood Coagulation Disorders
Changhai Hospital
Tongji Hospital; Qilu Hospital of Shandong University; First Affiliated Hospital... and other collaborators

Completed

Premedication Simethione Improves Visibility During Bowel Cleansing for Colonoscopy

Adenoma Detection Rate | Bowel Preparation Scale | the Amount of Air Bubble

China
Amgen

Completed

Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk (AMG145)

Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events

Japan
Medical College of Wisconsin

Withdrawn

Efficacy of Combination Therapy vs Placebo for Pediatric Functional Abdominal Pain (FAP)

Functional Dyspepsia | Irritable Bowel Syndrome | Functional Abdominal Pain

United States
Asan Medical Center
GE Healthcare

Completed

Oral Iohexol for Fecal/Fluid Tagging for CT Colonography: A Study to Improve Image Quality by Preventing Colonic Bubbles

Colorectal Neoplasms

Korea, Republic of
59th Medical Wing
Emergency Medicine Foundation

Completed

Prospective Randomized Trial of Bactrim on 7 Day Outcome in Patients With Uncomplicated Abscesses

Abscesses

United States

Search clinical trials for: evolocumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ghana

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations